|
Market Closed -
Sao Paulo
05:50:38 26/08/26 am AEST
|
5-day change | 1st Jan Change | ||
| 63.72 BRL | +1.43% |
|
+2.51% | +11.15% |
| 25/08 | Wall Street Wants Receipts |  |
| 25/08 | Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- GILD Stock
- GILD34 Stock
- Consensus Gilead Sciences, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
